1. Scrip
  2. >>Business

Organon Docks Into India’s Family Planning Program, Makes Early Gains

 
• By Anju Ghangurde

Organon's commercial director and lead for the South Asia region, Anjan Sen, discusses with Scrip the prospects of contraceptive Implanon NXT with its inclusion in India’s historic family planning program. The Merck spin-out is also on course to debut its Jada System this year, opening up new growth avenues as it disentangles and builds out operations in the region.

Anjan Sen
Anjan Sen, Commercial Director And Lead for The South Asia Region, Organon • Source: Organon

Organon appears to have had impressive wins in India for its women’s health portfolio as the Merck & Co., Inc. spin-out propels its business and disentangles itself from the parent entity in the country.

While the inclusion of Organon’s sub-dermal long-acting reversible contraceptive Implanon NXT (sold as Nexplanon in the US) in India’s long-running Family Planning Program (FPP) opens up significant opportunities for the company, Jada, its medical device to help control and treat abnormal postpartum uterine bleeding or hemorrhage has received the regulatory

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Scrip